Novo Nordisk asks FDA to block compounding pharmacies from making Ozempic copycats
Novo Nordisk has asked the Food and Drug Administration (FDA) to block compounding pharmacies from selling proprietary versions of its popular weight loss drug Wigoby and diabetes drug Ozempic, saying the drugs are too complex for pharmacies to manufacture safely. We are asking them to stop their production. Compounded anti-obesity drugs are sold at significantly […]